» Articles » PMID: 25277864

Recruited Metastasis Suppressor NM23-H2 Attenuates Expression and Activity of Peroxisome Proliferator-activated Receptor δ (PPARδ) in Human Cholangiocarcinoma

Overview
Journal Dig Liver Dis
Publisher Elsevier
Specialty Gastroenterology
Date 2014 Oct 4
PMID 25277864
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Peroxisome proliferator-activated receptor δ (PPARδ) is a versatile regulator of distinct biological processes and overexpression of PPARδ in cancer may be partially related to its suppression of its own co-regulators.

Aims: To determine whether recruited suppressor proteins bind to and regulate PPARδ expression, activity and PPARδ-dependent cholangiocarcinoma proliferation.

Methods: Yeast two-hybrid assays were done using murine PPARδ as bait. PPARδ mRNA expression was determined by qPCR. Protein expression was measured by western blot. Immunohistochemistry and fluorescence microscopy were used to determine PPARδ expression and co-localization with NDP Kinase alpha (NM23-H2). Cell proliferation assays were performed to determine cell numbers.

Results: Yeast two-hybrid screening identified NM23-H2 as a PPARδ binding protein and their interaction was confirmed. Overexpressed PPARδ or treatment with the agonist GW501516 resulted in increased cell proliferation. NM23-H2 siRNA activated PPARδ luciferase promoter activity, upregulated PPARδ RNA and protein expression and increased GW501516-stimulated CCA growth. Overexpression of NM23-H2 inhibited PPARδ luciferase promoter activity, downregulated PPARδ expression and AKT phosphorylation and reduced GW501516-stimulated CCA growth.

Conclusions: We report the novel association of NM23-H2 with PPARδ and the negative regulation of PPARδ expression by NM23-H2 binding to the C-terminal region of PPARδ. These findings provide evidence that the metastasis suppressor NM23-H2 is involved in the regulation of PPARδ-mediated proliferation.

Citing Articles

Molecular and nanoscale evaluation of N-cadherin expression in invasive bladder cancer cells under control conditions or GW501516 exposure.

Elie-Caille C, Lascombe I, Pechery A, Bittard H, Fauconnet S Mol Cell Biochem. 2020; 471(1-2):113-127.

PMID: 32519230 PMC: 7370938. DOI: 10.1007/s11010-020-03771-1.


PPAR Beta/Delta and the Hallmarks of Cancer.

Wagner N, Wagner K Cells. 2020; 9(5).

PMID: 32375405 PMC: 7291220. DOI: 10.3390/cells9051133.


Correlation of nm 23 expression with pharyngeal cancer and patient prognoses.

Wei W, Wei X, Liang X Oncol Lett. 2018; 16(5):5667-5672.

PMID: 30344722 PMC: 6176257. DOI: 10.3892/ol.2018.9375.


Exome sequencing of primary breast cancers with paired metastatic lesions reveals metastasis-enriched mutations in the A-kinase anchoring protein family (AKAPs).

Kjallquist U, Erlandsson R, Tobin N, Alkodsi A, Ullah I, Stalhammar G BMC Cancer. 2018; 18(1):174.

PMID: 29433456 PMC: 5810006. DOI: 10.1186/s12885-018-4021-6.

References
1.
Wagner P, Steeg P, Vu N . Two-component kinase-like activity of nm23 correlates with its motility-suppressing activity. Proc Natl Acad Sci U S A. 1997; 94(17):9000-5. PMC: 22999. DOI: 10.1073/pnas.94.17.9000. View

2.
Ouatas T, Salerno M, Palmieri D, Steeg P . Basic and translational advances in cancer metastasis: Nm23. J Bioenerg Biomembr. 2003; 35(1):73-9. DOI: 10.1023/a:1023497924277. View

3.
Xia X, Jung D, Webb P, Zhang A, Zhang B, Li L . Liver X receptor β and peroxisome proliferator-activated receptor δ regulate cholesterol transport in murine cholangiocytes. Hepatology. 2012; 56(6):2288-96. PMC: 3469731. DOI: 10.1002/hep.25919. View

4.
Ma D, Xing Z, Liu B, Pedigo N, Zimmer S, Bai Z . NM23-H1 and NM23-H2 repress transcriptional activities of nuclease-hypersensitive elements in the platelet-derived growth factor-A promoter. J Biol Chem. 2001; 277(2):1560-7. DOI: 10.1074/jbc.M108359200. View

5.
Steeg P . Metastasis suppressors alter the signal transduction of cancer cells. Nat Rev Cancer. 2003; 3(1):55-63. DOI: 10.1038/nrc967. View